Ubiquitin-Proteasome System in Neurodegenerative Disorders - PubMed (original) (raw)
Ubiquitin-Proteasome System in Neurodegenerative Disorders
Geeta Rao et al. J Drug Metab Toxicol. 2015.
Abstract
Cellular proteostasis is a highly dynamic process and is primarily carried out by the degradation tools of ubiquitin-proteasome system (UPS). Abnormalities in UPS function result in the accumulation of damaged or misfolded proteins which can form intra- and extracellular aggregated proteinaceous deposits leading to cellular dysfunction and/or death. Deposition of abnormal protein aggregates and the cellular inability to clear them have been implicated in the pathogenesis of a number of neurodegenerative disorders such as Alzheimer's and Parkinson's. Contrary to the upregulation of proteasome function in oncogenesis and the use of proteasome inhibition as a therapeutic strategy, activation of proteasome function would serve therapeutic objectives of treatment of neurodegenerative diseases. This review describes the current understanding of the role of the proteasome in neurodegenerative disorders and potential utility of proteasomal modulation therein.
Keywords: Brain pathologies; Neurodegenerative disorders; Proteasome modulators; Proteostasis; Ubiquitin-proteasome system.
Figures
Figure 1:. Ubiquitin-proteasome system (UPS).
UPS involves ubiquitination and proteolytic degradation of ubiquitinated proteins. Ubiquitin is first attached to the target protein via a cascade involving three distinct enzymes: ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). The ubiquitinated substrate is recognized, unfolded, and deubiquitinated by the 19S regulatory particle. The unfolded protein enters the 20S catalytic particle where it is degraded by the β1 (trypsin-like activity), β2 (caspase-like activity) and β5 (chymotrypsin-like activity) subunits.
Figure 2:. Various assemblies of proteasome.
The proteasome is a mono-capped or bi-capped cylindrical structure. The cylindrical core (20S or CP) is formed by two different types of protein subunits, α and β, which are arranged in four stacked heptameric rings enclosing a central cavity. The proteasome core particle can be capped with 19S or 11S activator complexes (a third activator complex Blm10/PA200 is not shown).
Figure 3:. UPS dysregulation in neurodegenerative disorders.
Almost all neurodisorders of contemporary interest are characterized by imbalanced UPS function, indicating the possible role of modulators of UPS as adjunct therapy.
Similar articles
- Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses.
Moore DJ, Dawson VL, Dawson TM. Moore DJ, et al. Neuromolecular Med. 2003;4(1-2):95-108. doi: 10.1385/NMM:4:1-2:95. Neuromolecular Med. 2003. PMID: 14528055 Review. - Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases.
Momtaz S, Memariani Z, El-Senduny FF, Sanadgol N, Golab F, Katebi M, Abdolghaffari AH, Farzaei MH, Abdollahi M. Momtaz S, et al. Front Physiol. 2020 Apr 28;11:361. doi: 10.3389/fphys.2020.00361. eCollection 2020. Front Physiol. 2020. PMID: 32411012 Free PMC article. - The ubiquitin-proteasome system in neurodegeneration.
McKinnon C, Tabrizi SJ. McKinnon C, et al. Antioxid Redox Signal. 2014 Dec 10;21(17):2302-21. doi: 10.1089/ars.2013.5802. Epub 2014 Feb 27. Antioxid Redox Signal. 2014. PMID: 24437518 Review. - The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders.
Di Domenico F, Lanzillotta C. Di Domenico F, et al. Adv Protein Chem Struct Biol. 2022;132:49-87. doi: 10.1016/bs.apcsb.2022.05.008. Epub 2022 Jun 9. Adv Protein Chem Struct Biol. 2022. PMID: 36088079 - Role of the ubiquitin-proteasome system in brain ischemia: friend or foe?
Caldeira MV, Salazar IL, Curcio M, Canzoniero LM, Duarte CB. Caldeira MV, et al. Prog Neurobiol. 2014 Jan;112:50-69. doi: 10.1016/j.pneurobio.2013.10.003. Epub 2013 Oct 22. Prog Neurobiol. 2014. PMID: 24157661 Review.
Cited by
- Programmable Protein Stabilization with Language Model-Derived Peptide Guides.
Hong L, Ye T, Wang TZ, Srijay D, Zhao L, Watson R, Vincoff S, Chen T, Kholina K, Goel S, DeLisa MP, Chatterjee P. Hong L, et al. Res Sq [Preprint]. 2024 Jul 26:rs.3.rs-4670386. doi: 10.21203/rs.3.rs-4670386/v1. Res Sq. 2024. PMID: 39108486 Free PMC article. Preprint. - NoRCE: non-coding RNA sets cis enrichment tool.
Olgun G, Nabi A, Tastan O. Olgun G, et al. BMC Bioinformatics. 2021 Jun 2;22(1):294. doi: 10.1186/s12859-021-04112-9. BMC Bioinformatics. 2021. PMID: 34078267 Free PMC article. - Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data.
Christodoulou CC, Zachariou M, Tomazou M, Karatzas E, Demetriou CA, Zamba-Papanicolaou E, Spyrou GM. Christodoulou CC, et al. Int J Mol Sci. 2020 Oct 8;21(19):7414. doi: 10.3390/ijms21197414. Int J Mol Sci. 2020. PMID: 33049985 Free PMC article. - The hGIDGID4 E3 ubiquitin ligase complex targets ARHGAP11A to regulate cell migration.
Bagci H, Winkler M, Grädel B, Uliana F, Boulais J, Mohamed WI, Park SL, Côté JF, Pertz O, Peter M. Bagci H, et al. Life Sci Alliance. 2024 Oct 10;7(12):e202403046. doi: 10.26508/lsa.202403046. Print 2024 Dec. Life Sci Alliance. 2024. PMID: 39389782 Free PMC article. - Proteostatic modulation in brain aging without associated Alzheimer's disease-and age-related neuropathological changes.
Andrés-Benito P, Íñigo-Marco I, Brullas M, Carmona M, Rio JAD, Fernández-Irigoyen J, Santamaría E, Povedano M, Ferrer I. Andrés-Benito P, et al. Aging (Albany NY). 2023 May 13;15(9):3295-3330. doi: 10.18632/aging.204698. Epub 2023 May 13. Aging (Albany NY). 2023. PMID: 37179123 Free PMC article.
References
- Hede SM, Savov V, Weishaupt H, Sangfelt O, Swartling FJ (2014) Oncoprotein stabilization in brain tumors. Oncogene 33: 4709–4721. - PubMed
- Caldeira MV, Salazar IL, Curcio M, Canzoniero LM, Duarte CB5 (2014) Role of the ubiquitin-proteasome system in brain ischemia: friend or foe? Prog Neurobiol 112: 50–69. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources